135 related articles for article (PubMed ID: 15527397)
1. "Tough but fair"? The active management of the New Zealand drug benefits scheme by an independent Crown agency.
Davis P
Aust Health Rev; 2004 Nov; 28(2):171-81. PubMed ID: 15527397
[TBL] [Abstract][Full Text] [Related]
2. The subsidy of pharmaceuticals in Australia: processes and challenges.
Sansom L
Aust Health Rev; 2004 Nov; 28(2):194-205. PubMed ID: 15527399
[TBL] [Abstract][Full Text] [Related]
3. PBS reform - a missed opportunity?
de Boer R
Aust Health Rev; 2009 May; 33(2):176-85. PubMed ID: 19563306
[TBL] [Abstract][Full Text] [Related]
4. Patient assistance programs: information is not our enemy.
Choudhry NK; Lee JL; Agnew-Blais J; Corcoran C; Shrank WH
Health Aff (Millwood); 2009; 28(3):843-4. PubMed ID: 19414896
[No Abstract] [Full Text] [Related]
5. Whither seniors' pharmacare: lessons from (and for) Canada.
Morgan SG; Barer ML; Agnew JD
Health Aff (Millwood); 2003; 22(3):49-59. PubMed ID: 12757272
[TBL] [Abstract][Full Text] [Related]
6. Exploring the implications of a fixed budget for new medicines: a study of reimbursement of new medicines in Australia and New Zealand.
Taylor C; Wonder M
Aust Health Rev; 2015 Sep; 39(4):455-461. PubMed ID: 25751688
[TBL] [Abstract][Full Text] [Related]
7. An Rx for reform: a Medicare prescription drug benefit.
Rak J
Health Matrix Clevel; 2002; 12(2):449-505. PubMed ID: 12430363
[No Abstract] [Full Text] [Related]
8. Incentives and pharmaceutical reimbursement reforms in Spain.
Puig-Junoy J
Health Policy; 2004 Feb; 67(2):149-65. PubMed ID: 14720633
[TBL] [Abstract][Full Text] [Related]
9. Health care reform and the pharmaceutical industry.
Mossinghoff GJ
Health Care Manag; 1994 Aug; 1(1):187-96. PubMed ID: 10152353
[TBL] [Abstract][Full Text] [Related]
10. Dilemmas in regulation of the market for pharmaceuticals.
Maynard A; Bloor K
Health Aff (Millwood); 2003; 22(3):31-41. PubMed ID: 12757269
[TBL] [Abstract][Full Text] [Related]
11. Government commitment and regulation of prescription drugs.
Frank RG
Health Aff (Millwood); 2003; 22(3):46-8. PubMed ID: 12757271
[TBL] [Abstract][Full Text] [Related]
12. The response to health care reform by the pharmaceutical industry.
Krulwich AS
Food Drug Law J; 1995; 50(1):1-22. PubMed ID: 10342983
[No Abstract] [Full Text] [Related]
13. Eliminating innovation: how price controls limit access.
Ingram J
J Leg Med; 2011 Jan; 32(1):115-28. PubMed ID: 21391059
[No Abstract] [Full Text] [Related]
14. The need for health care reform.
Mossinghoff GJ
Health Syst Rev; 1994; 27(3):5-6. PubMed ID: 10134516
[No Abstract] [Full Text] [Related]
15. Can we afford all this?
Dickerson JF
Time; 2003 Dec; 162(23):48-51. PubMed ID: 14712554
[No Abstract] [Full Text] [Related]
16. Pharmaceuticals, the state and the global harmonisation process.
Abraham J
Aust Health Rev; 2004 Nov; 28(2):150-60. PubMed ID: 15527395
[TBL] [Abstract][Full Text] [Related]
17. Voluntary patient assistance programs: additional federal oversight unwarranted.
Johnson K
Health Aff (Millwood); 2009; 28(3):835-8. PubMed ID: 19414894
[TBL] [Abstract][Full Text] [Related]
18. Reforming patient assistance programs: perfect world meets real world.
Weinberg M
Health Aff (Millwood); 2009; 28(3):839-42. PubMed ID: 19414895
[TBL] [Abstract][Full Text] [Related]
19. Restrictions on NHS prescribing in Australia.
Smith T
Br Med J; 1979 Jan; 1(6156):99-100. PubMed ID: 761010
[No Abstract] [Full Text] [Related]
20. Can price and regulatory controls replace free market competition in the drug industry?
Buc NL; Levitt GM
Healthspan; 1993 Nov; 10(10):30-2. PubMed ID: 10130839
[No Abstract] [Full Text] [Related]
[Next] [New Search]
